Under the agreement, the Serum Institute, one of India's largest makers of vaccines, will develop and manufacture paediatric vaccines, for which Cipla will then seek European Medicines Agency’s (EMA) approval and market the products in Europe.

The collaboration enables Cipla, India’s fourth largest drugmaker, to enter the vaccines market, in line with their ‘commitment to inclusive healthcare for the world’. Both companies have a common philosophy of ‘making vaccines/pharmaceutical products available at the most affordable prices’. The vaccines will be manufactured in the Serum Institute’s world class production facilities, which have been approved by the World Health Organization (WHO).

Cipla already exports to over 170 countries, but this deal will expand its presence in Europe, a region that contributed 5.7% to the company’s total revenue in the year to March 2013.

Cipla has already been making strides into Europe with the introduction of its respiratory products. The company has already launched its generic of GlaxoSmithKline’s asthma treatment Advair (fluticasone/salmeterol) in Croatia, Czech Republic, Germany, Slovakia and Sweden [1]. While in July 2014, Cipla also signed an exclusive partnership with BioQuiddity (a US company focussed on drug delivery) to market the anaesthetic OneDose ReadyfusOR (ropivacaine) for post-surgical pain management.

Related articles
Cipla petitions Indian government to revoke Onbrez patents

Cipla Medpro to collaborate with Teva for generics in South Africa

Reference
1.   GaBI Online - Generics and Biosimilars Initiative. Cipla and S&D Pharma make generics deal for Czech Republic and Slovakia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Dec 5]. Available from: www.gabionline.net/Pharma-News/Cipla-and-S-D-Pharma-make-generics-deal-for-Czech-Republic-and-Slovakia 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro PharmaCommunications International. All Rights Reserved.